APA (7th ed.) Citation

Yan, C., Li, Z., Li, J., Zhao, Q., Cao, W., Li, S., & Diao, R. Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China. Nature Portfolio.

Chicago Style (17th ed.) Citation

Yan, Chunyan, Zhengxiong Li, Jiayan Li, Quan Zhao, Wenxiu Cao, Shuqing Li, and Ruigang Diao. Cost-effectiveness of Benmelstobart and Anlotinib Plus Chemotherapy as First-line Therapy for Extensive-stage Small Cell Lung Cancer in China. Nature Portfolio.

MLA (9th ed.) Citation

Yan, Chunyan, et al. Cost-effectiveness of Benmelstobart and Anlotinib Plus Chemotherapy as First-line Therapy for Extensive-stage Small Cell Lung Cancer in China. Nature Portfolio.